Curatis Holding AG (XSWX:CURN) Other Long-Term Liabilities: CHF6.57 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:CURN Curatis Holding AG XSWX:CURN
33 GF Score
Price CHF20.40
! 7 Warning Signs
View Full Analysis

What is Curatis Holding AG Other Long-Term Liabilities?

Curatis Holding AG XSWX:CURN -4.67% 33 Other Long-Term Liabilities is CHF6.57 Mil as of Dec. 2025. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 7 warning signs investors should review.

Curatis Holding AG's other long-term liabilities for the quarter that ended in Dec. 2025 was CHF6.57 Mil.

Curatis Holding AG's quarterly other long-term liabilities declined from Dec. 2024 (CHF6.68 Mil) to Jun. 2025 (CHF6.65 Mil) and declined from Jun. 2025 (CHF6.65 Mil) to Dec. 2025 (CHF6.57 Mil).

Curatis Holding AG's annual other long-term liabilities increased from Dec. 2023 (CHF0.00 Mil) to Dec. 2024 (CHF6.68 Mil) but then declined from Dec. 2024 (CHF6.68 Mil) to Dec. 2025 (CHF6.57 Mil).

Curatis Holding AG Other Long-Term Liabilities Related Terms

Curatis Holding AG Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Curatis Holding AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curatis Holding AG Other Long-Term Liabilities Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
0.00 2.45 0.00 6.68 6.57

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 6.96 6.68 6.65 6.57
XSWX:CURN
33GF Score
Curatis Holding AG XSWX:CURN
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curatis Holding AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of CHF6.57 Mil mean?
Curatis Holding AG (XSWX:CURN) has a Other Long-Term Liabilities of CHF6.57 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Curatis Holding AG and its competitors.
Is Curatis Holding AG's Other Long-Term Liabilities too high?
Curatis Holding AG's current Other Long-Term Liabilities is CHF6.57 Mil. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's Other Long-Term Liabilities compare to ZTS and UTHR?
Curatis Holding AG's Other Long-Term Liabilities of CHF6.57 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Curatis Holding AG and its competitors. Curatis Holding AG's current Other Long-Term Liabilities is CHF6.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current Other Long-Term Liabilities of CHF6.57 Mil. The current Other Long-Term Liabilities is CHF6.57 Mil. Curatis Holding AG's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current Other Long-Term Liabilities is CHF6.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curatis Holding AG Business Description

Other Exchanges CURNz:UK0QNS:UK26U:Germany
Address Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score

Get the complete analysis for XSWX:CURN

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.40
Price